Edward M. Md Kaye Cytokinetics Inc (CYTK) insider trading activity

Edward M. Md Kaye is Director of CYTOKINETICS INC. Currently has a direct ownership of 9,977 shares of CYTK, which is worth approximately $662,871. The most recent transaction as insider was on Dec 01, 2025, when has been sold 28,064 shares (Common Stock) at a price of $66.72 per share, resulting in proceeds of $1,872,430. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 9.98K

57.05% 3M change

60.69% 12M change

Total Value Held $662,871

Edward M. MD Kaye Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 01 2025	SELL Open market or private sale	$1,872,430 $66.72 p/Share	28,064 Reduced 73.77%	9,977 Common Stock
Dec 01 2025	BUY Exercise of conversion of derivative security	$374,093 $13.33 p/Share	28,064 Added 42.45%	38,041 Common Stock
Nov 11 2025	SELL Open market or private sale	$336,789 $65.08 p/Share	5,175 Reduced 34.15%	9,977 Common Stock
Nov 11 2025	BUY Exercise of conversion of derivative security	$49,990 $9.66 p/Share	5,175 Added 25.46%	15,152 Common Stock
Oct 15 2025	BUY Grant, award, or other acquisition	$12,497 $62.8 p/Share	199 Added 1.96%	9,977 Common Stock
Oct 06 2025	SELL Open market or private sale	$405,420 $60.0 p/Share	6,757 Reduced 40.86%	9,778 Common Stock
Sep 30 2025	SELL Open market or private sale	$368,760 $55.08 p/Share	6,695 Reduced 28.82%	16,535 Common Stock

Sep 02 2025	SELL Open market or private sale	$337,800 $50.0 p/Share	6,756 Reduced 22.53%	23,230 Common Stock
Jul 15 2025	BUY Grant, award, or other acquisition	$12,467 $38.01 p/Share	328 Added 1.08%	29,986 Common Stock
Jun 05 2025	SELL Open market or private sale	$116,715 $32.1 p/Share	3,636 Reduced 10.92%	29,658 Common Stock
May 14 2025	BUY Grant, award, or other acquisition	-	7,333 Added 18.05%	33,294 Common Stock
Apr 15 2025	BUY Grant, award, or other acquisition	$12,493 $38.56 p/Share	324 Added 1.23%	25,961 Common Stock
Jan 02 2025	BUY Grant, award, or other acquisition	$12,477 $48.93 p/Share	255 Added 0.98%	25,637 Common Stock
Oct 01 2024	BUY Grant, award, or other acquisition	$12,466 $52.6 p/Share	237 Added 0.93%	25,382 Common Stock
Jul 01 2024	BUY Grant, award, or other acquisition	-	228 Added 0.9%	25,145 Common Stock
May 15 2024	BUY Grant, award, or other acquisition	-	5,600 Added 18.35%	24,917 Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	$12,449 $84.12 p/Share	148 Added 0.76%	19,317 Common Stock
Oct 02 2023	BUY Grant, award, or other acquisition	$12,490 $27.88 p/Share	448 Added 2.28%	19,169 Common Stock
Jul 03 2023	BUY Grant, award, or other acquisition	$12,476 $33.36 p/Share	374 Added 1.96%	18,721 Common Stock
May 10 2023	BUY Grant, award, or other acquisition	-	5,000 Added 21.42%	18,347 Common Stock
Apr 03 2023	BUY Grant, award, or other acquisition	$11,237 $37.71 p/Share	298 Added 2.18%	13,347 Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	$11,220 $44.35 p/Share	253 Added 1.9%	13,049 Common Stock
Oct 03 2022	BUY Grant, award, or other acquisition	$11,244 $51.11 p/Share	220 Added 1.69%	12,796 Common Stock
Aug 05 2022	SELL Open market or private sale	$571,400 $50.0 p/Share	11,428 Reduced 47.61%	12,576 Common Stock
Aug 05 2022	BUY Exercise of conversion of derivative security	$99,995 $8.75 p/Share	11,428 Added 32.25%	24,004 Common Stock

Also insider at

STOK

Stoke Therapeutics, Inc. Healthcare

RNA

Avidity Biosciences, Inc. Healthcare

Director

EMM

Edward M. Md Kaye

Director

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CYTK shares.

Notify only if

Value

Insider Trading

Get notified when an Cytokinetics Inc insider buys or sells CYTK shares.

Notify only if

Operation

Value

Type

News

Receive news related to CYTOKINETICS INC

Track Activities on CYTK

Account